Detralex-phlebosclerosing treatment. Results of the national multicenter follow up programme VEIN ACT PROLONGED-C1

Bogachev V.Yu., Boldin B.V., Turkin P.Yu.

Department of Faculty Surgery No 2, Russian National Research Medical University named after N.I. Pirogov, Moscow, Russia

Presented herein are the results of the observational follow up study programme dedicated to the assessment of appropriate use of adjuvant therapy with Detralex while carrying out phlebosclerosing treatment in patients suffering from dilated intradermal veins (clinical class C1 according to the CEAP classification).

A conclusion was drawn that administration of Detralex for 60 days decreased the incidence rate of typical undesirable side events after phlebosclerosing therapy, thus making the use of this drug appropriate in routine clinical practice.

KEY WORDS: sclerotherapy, reticular veins, telangiectasias, detral.

P. 106

« Back